- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05248555
Det nationale australske HCV Point-of-Care-testprogram - minimalt datasæt
Det nationale australske HCV Point-of-Care-testprogram: En observationel kohorteundersøgelse til at evaluere brugen af finger-stick Point-of-care Hepatitis C-testning for at forbedre diagnosticering og behandling af HCV-infektion - minimalt datasæt
The National Australian HCV Point-of-Care Testing Program will establish an observational cohort to evaluate whether scale-up of finger-stick point-of-care HCV testing increases diagnosis and treatment for HCV infection. Participants will be recruited from settings providing services to people with a risk factor for the acquisition of HCV infection (including drug treatment clinics, needle and syringe programs, homelessness settings, mental health services, prisons, and mobile outreach). All participants who undergo HCV point-of-care testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The advent of simple direct-acting antiviral hepatitis C (HCV) therapies with cure rates >95% is one of the greatest medical advances in decades, having led to a reversal in liver-related mortality. In Australia, treatment uptake has declined between 2016 (32,000 treated) and 2019/20 (2019: 11,500; 2020: 8,500).1 Progress towards HCV elimination has been impeded by COVID-19, affecting the delivery of national and state-based HCV strategies. Improving HCV treatment uptake to reduce disease burden is a key aim of global, national and state-based HCV strategies.2-4
Scale-up of HCV testing and treatment will be required to achieve elimination by 2030. Current diagnostic pathways require multiple visits to a practitioner reducing the proportion who receive a diagnosis. In Australia, 81% of people have had HCV antibody testing (indicates exposure), but only 47% have been HCV RNA tested (indicates active infection and the need for HCV treatment).5 Mathematical modelling suggests that HCV RNA testing needs to increase by at least 50% annually to achieve elimination in Australia by 2030.6
The Kirby Institute is an international leader in research evaluating the Xpert HCV assay (Grebely Lancet Gastro Hep 2017), having built a large network of Xpert platforms for HCV testing in needle and syringe programs, prisons, drug treatment clinics, tertiary hospitals, and Aboriginal Community Controlled Health Service. In Kirby-led research, point-of-care HCV testing interventions in needle and syringe programs and prisons have resulted in high HCV treatment uptake (70-90%). The Kirby Institute and Flinders University also have a strong track record of implementing point-of-care testing for STIs and COVID-19, providing an ideal foundation to scale-up Xpert HCV testing in Australia.
The Kirby Institute and Flinders University will establish the Australian National HCV Point-of-care Testing Program for the scale-up of point-of-care HCV RNA testing in services with high prevalence of HCV infection, including community health centres, drug treatment clinics, needle and syringe programs, and prisons. This program will include the development of standard operating procedures, logistics/deployment, initial set-up, an operator training program, and quality assurance and competency assessment program.
An observational cohort study will be established to evaluate HCV treatment uptake following scale-up of point-of-care HCV testing among people with a risk factor for acquisition of HCV infection or people attending a service caring for people with risk factors for the acquisition of HCV infection.
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection. All participants who undergo point-of-care HCV testing at the study site will be included in the data collection. Participants will not receive treatment as a part of this study. Participants who are HCV RNA positive will be linked to standard of care for any other clinical assessments and treatment initiation.
Undersøgelsestype
Tilmelding (Anslået)
Kontakter og lokationer
Studiekontakt
- Navn: Simon Comben, BSc, MN
- Telefonnummer: +6193480777
- E-mail: scomben@kirby.unsw.edu.au
Undersøgelse Kontakt Backup
- Navn: David Silk, BSc
- Telefonnummer: +61293850900
- E-mail: dsilk@kirby.unsw.edu.au
Studiesteder
-
-
New South Wales
-
Sydney, New South Wales, Australien
- Aktiv, ikke rekrutterende
- Justice Health and Forensic Mental Health Network
-
-
Queensland
-
Aldershot, Queensland, Australien, 4650
- Rekruttering
- Maryborough Correctional Centre
-
Kontakt:
- Ashley Willman
- Telefonnummer: (07) 4123 7600
- E-mail: ashley.willmann@health.qld.gov.au
-
Brisbane, Queensland, Australien, 4000
- Rekruttering
- QuIHN
-
Kontakt:
- Nicholas Alexander
- Telefonnummer: 3620 8111
- E-mail: nalexander@quihn.org
-
Cairns, Queensland, Australien
- Rekruttering
- Lotus Glen Correctional Centre
-
Kontakt:
- Darren Russell
-
Ledende efterforsker:
- Darren Russell
-
Coorparoo, Queensland, Australien, 4151
- Afsluttet
- Hepatitis Queensland
-
Ipswich, Queensland, Australien
- Rekruttering
- West Moreton Hospital and Health Service
-
Kontakt:
- Blake Ponting
-
Ledende efterforsker:
- Blake Ponting
-
Rathdowney, Queensland, Australien, 4287
- Ikke rekrutterer endnu
- Palen Creek Correctional Centre
-
Kontakt:
- Mike Hurley
- Telefonnummer: (07) 5544 3700
- E-mail: mike.hurley@corrections.qld.gov.au
-
Townsville, Queensland, Australien
- Rekruttering
- Townsville Correctional Centre
-
Kontakt:
- John Morey
-
Ledende efterforsker:
- John Morey
-
Woodford, Queensland, Australien
- Rekruttering
- Woodford Correctional Centre
-
Kontakt:
- Rajendra Prakash
-
Ledende efterforsker:
- Rajendra Prakash
-
-
South Australia
-
Hackney, South Australia, Australien, 5069
- Rekruttering
- Hepatitis SA
-
Kontakt:
- Lisa Carter
- Telefonnummer: (08) 8362 8443
- E-mail: lisa@hepatitissa.asn.au
-
Marden, South Australia, Australien, 5070
- Ikke rekrutterer endnu
- South Australian Prison Health Service
-
Kontakt:
- Tom Turnbull
-
Ledende efterforsker:
- Tom Turnbull
-
Mount Gambier, South Australia, Australien, 5290
- Rekruttering
- Mount Gambier Priosn
-
Kontakt:
- William Galloway
-
Ledende efterforsker:
- William Galloway
-
-
Victoria
-
Fitzroy, Victoria, Australien, 3065
- Aktiv, ikke rekrutterende
- St Vincent's Correctional Health Services
-
Melbourne, Victoria, Australien, 3000
- Rekruttering
- Medically Supervised Injecting Room
-
Kontakt:
- Nathan Stam
-
Ledende efterforsker:
- Nathan Stam
-
Ravenhall, Victoria, Australien, 3023
- Rekruttering
- Dame Phyllis Frost Centre
-
Kontakt:
- Katelyn Mannix
- Telefonnummer: 1300 492 202
- E-mail: katelyn.mannix@wh.org.au
-
Ravenhall, Victoria, Australien, 3023
- Rekruttering
- Geo Healthcare - The Geo Group Australia Pty Ltd
-
Kontakt:
- David Grace
-
Ledende efterforsker:
- David Grace
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Prøveudtagningsmetode
Studiebefolkning
Participants will be recruited from settings that provide services to people with a risk factor for the acquisition of HCV infection, including drug treatment clinics, needle and syringe programs, prisons, mobile outreach services, community health services, mental health services, homelessness services, and other appropriate settings nationally. It is anticipated approximately 40,000 participants will be screened for HCV infection using point-of-care HCV testing.
Beskrivelse
Inclusion Criteria:
- ≥ 18 years of age.
- Received point-of-care HCV testing.
Exclusion Criteria:
- Nil
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Observationsmodeller: COHORT
- Tidsperspektiver: PROSPECTIVE
Kohorter og interventioner
Gruppe / kohorte |
Intervention / Behandling |
|---|---|
|
People at risk of HCV acquisition
Clinic staff will offer HCV point-of-care testing to participants as they access services. Testing will be performed using point-of-care HCV RNA testing. |
Participants will be offered finger-stick point-of-care testing for HCV |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of HCV infected participants who initiate HCV treatment at 12 weeks
Tidsramme: 12 Weeks from enrolment
|
To evaluate the proportion of HCV infected (HCV RNA quantifiable) participants who initiate HCV treatment at 12 weeks following finger-stick point-of-care HCV RNA testing. |
12 Weeks from enrolment
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
The proportion of participants who accept point-of-care testing
Tidsramme: 2 years from recruitment commencement
|
To evaluate the proportion of people who accept point-of-care testing among those offered testing. |
2 years from recruitment commencement
|
|
The prevalence of HCV infection amongst study participants tested
Tidsramme: 2 years from recruitment commencement
|
To evaluate the prevalence of current HCV infection (HCV RNA quantifiable) among people tested. |
2 years from recruitment commencement
|
|
To evaluate the time to HCV treatment uptake among HCV RNA positive participants
Tidsramme: 52 weeks
|
To evaluate the length of time participants take to initiate HCV treatment after diagnosis |
52 weeks
|
|
To evaluate proportion of HCV RNA positive participants who initiate HCV treatment
Tidsramme: 52 weeks
|
To evaluate the proportion of HCV RNA positive participants who initiate HCV treatment at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
|
To evaluate the proportion of participants who complete HCV (DAA) treatment
Tidsramme: 52 weeks
|
To evaluate the proportion of participants who complete HCV direct-acting antiviral (DAA) treatment. |
52 weeks
|
|
To evaluate the proportion of participants who achieve an SVR
Tidsramme: 12 weeks
|
To evaluate the proportion of participants who achieve an SVR (defined as HCV RNA below the lower limit of quantitation at post treatment week 12). |
12 weeks
|
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months
Tidsramme: 52 weeks
|
To evaluate the proportion of participants who are HCV RNA negative at 12 months (52 weeks) following finger-stick point-of-care HCV RNA testing. |
52 weeks
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- VHCRP2104
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
Request to share IPD will be considered by the protocol steering committee on individual basis
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .